CJC-1295 in Australia: legal status and listed suppliers

Legal status in Australia

Prescription only. Listed in Schedule 4 of the Poisons Standard (June 2026).

As understood at 2026-09-22. Verify with the TGA.

What CJC-1295 is

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), modified so that it binds to the body's own albumin after injection and lasts far longer than the natural hormone, with a half-life of about eight days. Several listed suppliers also sell a product labelled 'CJC-1295 no DAC', which lacks that modification; it is a different molecule from the one in the trials below.

Full CJC-1295 page: targets and research →

Listed suppliers in Australia

6 of the 10 suppliers we list in Australia list CJC-1295. Listed, not endorsed: each row is the supplier’s own stated terms.

Au Peptide Labs Australia For laboratory research use only. Not for human consumption. Aussie Peptides Australia Research use only. Statements have not been evaluated by the TGA. We do not ship internationally at this time. Australian Peptide Site Australia Intended for laboratory and scientific research use only. Next Gen Peptides Australia Not for human consumption. Peptopia Australia For in vitro research use only. Not for human or veterinary consumption. Not evaluated or approved by the TGA. Synapse Peptides Australia Australia All products are supplied strictly for research purposes only and are not intended for human or veterinary use.

Clinical Research

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA (2006). Journal of Clinical Endocrinology & Metabolism. human healthy adults, phase I, two small dose-ranging studies

Pulsatile Secretion of Growth Hormone (GH) Persists during Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog

Ionescu M, Frohman LA (2006). The Journal of Clinical Endocrinology & Metabolism. human healthy men aged 20 to 40, blood sampled every 20 minutes over a 12-hour overnight period before and a week after a single injection